Im Focus Onkologie

, Volume 15, Issue 1–2, pp 56–60

Sicherung des onkologischen Therapieerfolgs durch Supportivtherapie

Dermale Toxizität durch EGFR-Inhibitoren
Fortbildung
  • 12 Downloads

Reagiert die Haut unter anderem mit Exanthemen auf eine Therapie, die den Rezeptor des epidermalen Wachstumsfaktors hemmt, ist dies ein gutes Zeichen für den Behandlungserfolg. Trotzdem leiden die Patienten unter der Toxizität. Wie lässt sie sich in den Griff bekommen?

Literatur

  1. 1.
    Atherton PJ et al. Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care Cancer. 2011 Sep 16. [Epub ahead of print].Google Scholar
  2. 2.
    Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004. 351(4):337–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Gerber PA et al. More on aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010; 364(5):486–7.Google Scholar
  4. 4.
    Gutzmer R et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges. 2011;9(3):195–203.PubMedGoogle Scholar
  5. 5.
    Jatoi A et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Supp Care Cancer. 2011.19(10): 1601–7.CrossRefGoogle Scholar
  6. 6.
    Jatoi A et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113(4):847–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Lacouture ME et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supp Care Cancer. 2011;19(8):1079–95.CrossRefGoogle Scholar
  8. 8.
    Lacouture ME et al. Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a phase II, open-label, randomised trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2011;28:1351–7.CrossRefGoogle Scholar
  9. 9.
    Leveque D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363(17):1680–1; author reply 1681.PubMedCrossRefGoogle Scholar
  10. 10.
    Mir OB et al. More on aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;364(5):487.Google Scholar
  11. 11.
    Perez-Soler R et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004. 22(16):3238–47.PubMedCrossRefGoogle Scholar
  12. 12.
    Potthoff K et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011;22(3):524–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Rowinsky EK et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004;22(15):3003–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Saltz LB et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Santini D et al. J Clin Oncol. 2011; 29 (suppl; abstr 9078).Google Scholar
  16. 16.
    Scope A et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34): 5390–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Vincenzi B et al. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363(4): 397–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Wacker B et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13(13):3913–21.PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  1. 1.Universitätsklinik für Innere Medizin IV Onkologie/Hämatologie/Hämostaseologie Universitätsklinikum HalleHalle/SaaleDeutschland
  2. 2.HalleDeutschland

Personalised recommendations